Literature DB >> 10888246

Modulation of neutrophil migration and superoxide anion release by metoprolol.

S Dunzendorfer1, C J Wiedermann.   

Abstract

In addition to having anti-sympathotonic effects, beta-blockers are thought to have some adrenoceptor-independent properties. Such ancillary effects are described for carvedilol acting as oxygen radical scavenger and for propranolol which blocks protein kinase C and phosphatidate phosphohydrolase. The goal of our in vitro experiments was to identify ancillary effects of the widely used beta-blockers metoprolol and atenolol in neutrophils. Neutrophil chemotaxis was tested using the leading front assay in a modified Boyden microchemotaxis chamber. Respiratory burst activity was detected fluorometrically. Inhibition of protein kinase C activity was tested with purified alpha-, beta- and gamma-isoenzyme preparation. Metoprolol dose-dependently inhibited formyl peptide-stimulated neutrophil chemotaxis and formylpeptide- and phorbol myristate acetate-triggered oxygen free radical production. These actions were not affected by the competitive presence of the beta-receptor agonist, orciprenaline. Effects of metoprolol, as well as of propranolol, and the signaling enzyme blockers were strongly time dependent. Propranolol mimicked effects of staurosporine on respiratory burst, whereas the effects of metoprolol were similar to bisindolylmaleimide, a specific protein kinase C blocker. Atenolol, a hydrophilic beta-blocker, neither affected neutrophil chemotaxis nor respiratory burst. In a cell-free system, metoprolol did not interfere with the activity of the purified protein kinase C alpha-, beta- and gamma-isoenzymes. Adrenoceptor-independent inhibition of neutrophil chemotaxis and free radical production is a novel mode of action of metoprolol that may be relevant for beneficial effects ot the beta-blocker in heart failure and endothelial preconditioning.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888246     DOI: 10.1006/jmcc.2000.1148

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

1.  Regulation of Adrenergic, Serotonin, and Dopamine Receptors to Inhibit Diabetic Retinopathy: Monotherapies versus Combination Therapies.

Authors:  Timothy S Kern; Yunpeng Du; Jie Tang; Chieh Allen Lee; Haitao Liu; Alyssa Dreffs; Henri Leinonen; David A Antonetti; Krzysztof Palczewski
Journal:  Mol Pharmacol       Date:  2021-08-15       Impact factor: 4.054

2.  The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion.

Authors:  Borja Ibanez; Giovanni Cimmino; Susanna Prat-González; Gemma Vilahur; Randolph Hutter; Mario J García; Valentin Fuster; Javier Sanz; Lina Badimon; Juan J Badimon
Journal:  Int J Cardiol       Date:  2009-11-12       Impact factor: 4.164

3.  Neutrophil stunning by metoprolol reduces infarct size.

Authors:  Jaime García-Prieto; Rocío Villena-Gutiérrez; Mónica Gómez; Esther Bernardo; Andrés Pun-García; Inés García-Lunar; Georgiana Crainiciuc; Rodrigo Fernández-Jiménez; Vinatha Sreeramkumar; Rafael Bourio-Martínez; José M García-Ruiz; Alfonso Serrano Del Valle; David Sanz-Rosa; Gonzalo Pizarro; Antonio Fernández-Ortiz; Andrés Hidalgo; Valentín Fuster; Borja Ibanez
Journal:  Nat Commun       Date:  2017-04-18       Impact factor: 14.919

4.  Plasma Metabolic Signature of Atherosclerosis Progression and Colchicine Treatment in Rabbits.

Authors:  Mario Augusto Izidoro; Alberto Cecconi; María Isabel Panadero; Jesús Mateo; Joanna Godzien; Jean Paul Vilchez; Ángeles López-Gonzálvez; Jesús Ruiz-Cabello; Borja Ibañez; Coral Barbas; Francisco J Rupérez
Journal:  Sci Rep       Date:  2020-04-27       Impact factor: 4.379

5.  Effects of Arginine Vasopressin on Migration and Respiratory Burst Activity in Human Leukocytes.

Authors:  Franz J Wiedermann; Kathrin Watzinger; Martina Stichlberger; Michael Joannidis; Christian Kaehler; Wolfgang Lederer
Journal:  Open Med (Wars)       Date:  2018-05-09

6.  Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation.

Authors:  Agustín Clemente-Moragón; Mónica Gómez; Rocío Villena-Gutiérrez; Doménica V Lalama; Jaime García-Prieto; Fernando Martínez; Fátima Sánchez-Cabo; Valentín Fuster; Eduardo Oliver; Borja Ibáñez
Journal:  Eur Heart J       Date:  2020-12-07       Impact factor: 29.983

7.  Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis.

Authors:  Yan-Li Yang; Zi-Jian Xiang; Jing-Hua Yang; Wen-Jie Wang; Zhi-Chun Xu; Ruo-Lan Xiang
Journal:  Eur Heart J       Date:  2020-12-07       Impact factor: 29.983

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.